ArticleInternational journal of clinical and experimental pathology2015
Expression of ITGB1 predicts prognosis in colorectal cancer: a large prospective study based on tissue microarray.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 39 citations in OpenAlex.
- Tissue-derived extracellular matrix hydrogels instruct epigenetic adaptation in metastatic colonization.Bioactive materials · 2027Article
- High expression of LIMD2 predicts a poor prognosis and promotes migration of colon cancer cells.Discover oncology · 2025Article
- Circular RNAs and cervical cancer: friends or foes? A landscape on circRNA-mediated regulation of key signaling pathways involved in the onset and progression of HPV-related cervical neoplasms.Cell communication and signaling : CCS · 2024Review
- The characteristics and the multiple functions of integrin β1 in human cancers.Journal of translational medicine · 2023Review
- Integrin β5 is an independent prognostic marker for intrahepatic cholangiocarcinoma in a Chinese population.Experimental and therapeutic medicine · 2023Article
- Extracellular Vesicle Antibody Microarray for Multiplexed Inner and Outer Protein Analysis.ACS sensors · 2022Article
- Tracking the Molecular Scenarios for Tumorigenic Remodeling of Extracellular Matrix Based on Gene Expression Profiling in Equine Skin Neoplasia Models.International journal of molecular sciences · 2022Article
- Yin Yang 1 regulates ITGAV and ITGB1, contributing to improved prognosis of colorectal cancer.Oncology reports · 2022Article
- Transcriptomic analysis reveals high ITGB1 expression as a predictor for poor prognosis of pancreatic cancer.PloS one · 2022Article
- Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression.World journal of gastrointestinal oncology · 2021Review
- Neuromedin U induces an invasive phenotype in CRC cells expressing the NMUR2 receptor.Journal of experimental & clinical cancer research : CR · 2021Article
- Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer.Biomedicines · 2021Article
- The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials.Cancers · 2021Review
- Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Article
- Atractyloside targets cancer-associated fibroblasts and inhibits the metastasis of colon cancer.Annals of translational medicine · 2020Article
- BRAFOncogene · 2020Article
- Article
- Inhibition of ITGB1 enhance the anti-tumor effect of cetuximab in colorectal cancer cell.Medicine · 2020Article
- Mechanical Cues Affect Migration and Invasion of Cells From Three Different Directions.Frontiers in cell and developmental biology · 2020Review
- Functional Interplay Between Collagen Network and Cell Behavior Within Tumor Microenvironment in Colorectal Cancer.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundITGB1 is a heterodimeric cell-surface receptor involved in cell functions such as proliferation, migration, invasion and survival. The aim of this study was to assess ITGB1 expression in colorectal cancer and correlate it with clinicopathological features, as well as to evaluate its potential prognostic significance. MATERIALS AND
methodsIn this study, we examined the expression of ITGB1 using tissue microarrays containing analyzed specimens by immunohistochemistry. ITGB1 expression was further correlated with clinicopathological and prognostic data. The prognostic significance was assessed using Kaplan-Meier survival estimates and log-rank tests. A multivariate study with the Cox's proportional hazard model was used to evaluate the prognostic aspects.
resultsITGB1 expression was present in 88.5% of the analyzed specimens. Significant differences in ITGB1 expression were found between normal mucosa and carcinomas (P<0.001). High ITGB1 expression was associated with poor prognosis, and it independently correlated with shortened overall survival and disease-free survival in colorectal cancer patients (P<0.001). More so, ITGB1 expression, bowel wall invasion, lymph node metastasis and distant metastasis were independent prognostic factors for overall survival. Additionally, significant differences in ITGB1 expression were observed in adenomas and tumors from patients with familial adenomatous polyposis compared to normal colon mucosa (P<0.05)
conclusionThe results of this study indicate that ITGB1 overexpression in colorectal tumors is associated with poor prognosis, as well as aggressive clinicopathological features. Therefore, ITGB1 expression could be used as potential prognostic predictor in colorectal cancer patients.
Indexed as
Identifiers
26722470PMC4680415W2419559956What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.